Literature DB >> 35700955

Synthesis and evaluation of Diaza-Crown Ether-Backboned chelator containing hydroxamate groups for Zr-89 chelation chemistry.

Shuyuan Zhang1, Haixing Wang1, Siyuan Ren1, Yanda Chen1, Dijie Liu2, Mengshi Li2, Edwin Sagastume3, Hyun-Soon Chong4.   

Abstract

Zirconium-89 (89Zr) has been explored for molecularly targeted positron emission tomography (PET) imaging of various diseases. We synthesized and evaluated a novel chelator (DA-18C6-BHA) for 89Zr. The new chelator is structured on a macrocyclic backbone (1,10-diaza-18-crown-6) and contains hydroxamates as acyclic donor groups. The new chelator ((DA-18C6-BHA) was rapidly labeled with 89Zr under mild conditions. The 89Zr-labeled DA-18C6-BHA complex remained stable in human serum and apotransferrin for 7 days. When challenged with excess EDTA solution, 89Zr-labeled DA-18C6-BHA was shown to hold 89Zr without losing considerable radioactivity to EDTA. The 89Zr-labeled DA-18C6-BHA complex displayed high complex stability in normal mice as evidenced by low bone uptake.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chelator; PET Imaging; Zr-89

Mesh:

Substances:

Year:  2022        PMID: 35700955      PMCID: PMC9308756          DOI: 10.1016/j.bmcl.2022.128847

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.940


  15 in total

Review 1.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

2.  The Impact of Emerging Bioconjugation Chemistries on Radiopharmaceuticals.

Authors:  Rachael Fay; Jason P Holland
Journal:  J Nucl Med       Date:  2019-03-22       Impact factor: 10.057

3.  Radioactive Main Group and Rare Earth Metals for Imaging and Therapy.

Authors:  Thomas I Kostelnik; Chris Orvig
Journal:  Chem Rev       Date:  2018-10-31       Impact factor: 60.622

4.  Development of bifunctional chelates bearing hydroxamate arms for highly efficient (64)Cu radiolabeling.

Authors:  Samia Ait-Mohand; Céline Denis; Geneviève Tremblay; Michel Paquette; Brigitte Guérin
Journal:  Org Lett       Date:  2014-08-18       Impact factor: 6.005

Review 5.  The evolution of iron chelators for the treatment of iron overload disease and cancer.

Authors:  Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2005-12       Impact factor: 25.468

6.  Recommendations on the use of 18F-FDG PET in oncology.

Authors:  James W Fletcher; Benjamin Djulbegovic; Heloisa P Soares; Barry A Siegel; Val J Lowe; Gary H Lyman; R Edward Coleman; Richard Wahl; John Christopher Paschold; Norbert Avril; Lawrence H Einhorn; W Warren Suh; David Samson; Dominique Delbeke; Mark Gorman; Anthony F Shields
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

7.  Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89.

Authors:  W E Meijs; J D Herscheid; H J Haisma; H M Pinedo
Journal:  Int J Rad Appl Instrum A       Date:  1992-12

Review 8.  Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges.

Authors:  Tapan K Nayak; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2009-05-20       Impact factor: 4.774

Review 9.  89 Zr-ImmunoPET companion diagnostics and their impact in clinical drug development.

Authors:  Brooke N McKnight; Nerissa T Viola-Villegas
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-12       Impact factor: 1.921

Review 10.  89Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89Zr Radiochemistry.

Authors:  Sandra Heskamp; René Raavé; Otto Boerman; Mark Rijpkema; Victor Goncalves; Franck Denat
Journal:  Bioconjug Chem       Date:  2017-08-24       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.